Antibody Monotherapy Shows Promise in Neuromyelitis Optica

Satralizumab as monotherapy is effective vs placebo for reducing risk of relapses in patients with autoimmune neuromyelitis optica spectrum disorder (NMOSD), new research suggests.
Medscape Medical News

Source link

Related posts

JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results


clinical neurology; +378 new citations


Digital Journal: Essential science: What different sides of the brain are tell us


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World